InsidersTradesSigma
Iovance Biotherapeutics, INC.: insider trades · United States · SEC (Form 4)
SEC:iovance-biotherapeutics-inc-9db83dUS·SEC (Form 4)
Discover the full insider trade history of Iovance Biotherapeutics, INC., a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). The latest transaction was filed on 16 June 2022 — Levée d'options. Among the most active insiders: BILINSKY IGOR. All data is accessible without an account.
8
Insider Decl.
0
Thresholds
€3m
5 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
3.58 €
Analyst consensus
Valuation
P/Book2.2x
Beta0.69
Balance sheet & cash
Debt / Equity7%
Profitability & ownership
ROE-47.5%
ROA-23.6%
% insiders0.3%
% institutions67.4%
Last declaration on 16 June 2022
Declarations8 total
Executives◇Options12SEC
018,850 shares0
Common Stock
SEC:0001104659-22-071964:0·
Executives◇Options12SEC
019,690 shares0
Common Stock
SEC:0001104659-22-071967:0·
Executives◇Options20SEC
018,850 shares0
Common Stock
SEC:0001104659-22-071965:0·
Executives▲Purchase◆Signal · 45SEC
€13,8342,187 shares@ €6.3256100.0% of flow
Common Stock
SEC:0001104659-22-067761:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 45SEC
€3m500,000 shares@ €6.3062100.0% of flow
Common Stock
SEC:0001104659-22-067757:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 45SEC
€47,1287,500 shares@ €6.2837100.0% of flow
Common Stock
SEC:0001104659-22-067762:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 45SEC
€63,72210,000 shares@ €6.3722100.0% of flow
Common Stock
SEC:0001104659-22-067763:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 56SEC
€6,0451,000 shares@ €6.0446100.0% of flow
Common Stock
SEC:0001104659-22-067758:0·
Ideal exit: 26 Feb 2023 (T+270)
8 of 8 declarations